Follows adults with heart-related transthyretin amyloidosis treated with vutrisiran
Observes adults with transthyretin amyloidosis heart disease receiving vutrisiran in routine care.
Plain-language title generated from the registry record
Registry title: DemonsTTRate: A Global, Observational, Multicenter, Long-term Study of Patients With ATTR-CM in a Real-World Setting
Key facts
- Where
- Heidelberg, Munich, Münster, and Würzburg, GermanySee the 4 sites
Where in Germany
- HeidelbergHeidelberg, GermanyTaking people
- MunichMunich, GermanyTaking people
- MünsterMünster, GermanyTaking people
- WürzburgWürzburg, GermanyTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Alnylam Pharmaceuticals
- Trial code
- NCT07358078
- Record updated
- 9 October 2026
- Original description
The purpose of this study is to:Read full original descriptionShow less
DemonsTTRate: A Global, Observational, Multicenter, Long-term Study of Patients With Transthyretin-Mediated Amyloidosis With Cardiomyopathy in a Real-World Setting
The purpose of this study is to:
* Describe the clinical characteristics of adult patients with transthyretin-mediated amyloidosis with cardiomyopathy (ATTR-CM) treated with vutrisiran in routine clinical care * Describe treatment patterns of adult patients with ATTR-CM treated with vutrisiran in routine clinical care * Assess health-related quality of life (HRQOL) in adult patients with ATTR-CM treated with vutrisiran in routine clinical care * Assess healthcare resource use (HCRU) in adult patients with ATTR-CM treated with vutrisiran in routine clinical care * Compare the long-term effectiveness of vutrisiran versus other approved ATTR-CM treatments in routine clinical care
Inclusion: Has a diagnosis of ATTR-CM; Is initiating treatment with vutrisiran or another approved ATTR-CM therapy.
Exclusion: Is enrolled in an interventional clinical trial.